drug-discovery

To search ChEMBL for bioactive compounds and evaluate drug-likeness, query a specific target to retrieve top active compounds with pChEMBL scores, then compute Lipinski Ro5 and Veber rules to screen candidates.

Yes, you can perform ADMET interpretation and safety assessment without API keys by using deterministic workflows to fetch OpenFDA interactions and OpenTargets disease associations for risk evaluation.

Yes, you need Python 3 and curl to retrieve bioactivity data and compute drug-likeness metrics, as the workflow operates without API keys using these tools to fetch target data and surface interactions.

The best way to integrate OpenFDA and OpenTargets data for target-driven lead discovery is using a unified workflow that cross-sources interactions and disease associations to inform safety assessment alongside property screening.

Cross-source data synthesis across PubChem, ChEMBL, and OpenTargets works by applying deterministic workflows to fetch target data, compute drug-likeness metrics, and surface interactions for comprehensive property screening.

Limitations of using open pharma databases for ADMET prediction include relying on deterministic workflows that fetch existing data rather than generating novel predictions, requiring careful interpretation of surfaced interactions for accurate risk assessment.